The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for month s and eliminates the patient’s need for on-demand drugs (such as Viagra and Cialis), could become the future treatment of choice for this common problem, according to a paper in the most recent issue of Human Gene Therapy. (Source: EurekAlert! – Biology)
AlexzaPharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiateda Phase IIa clinical trial with AZ-002 (Staccato(TM) alprazolam) inpatients with panic disorder. AZ-002 is an inhalation product candidatebeing developed for the acute treatment of panic attacks associated withpanic disorder. The Phase IIa clinical trial is an in-clinic proof of concept study. [click link for full article] (Source: Mental Health News From Medica (more…)
The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient’s need for on-demand drugs (such as Viagra and Cialis), could become the future treatment of choice for this common problem, according to a paper in the most recent issue of Human Gene Therapy. [click link for full article] (Source: Health News from Medic al News Today)
The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient’s need for on-demand drugs (such as Viagra and Cialis), could become the future t reatment of choice for this common problem, according to a paper in the most recent issue of Human Gene Therapy. [click link for full article] (Source: Genetics News From Medical News Today)
MedWorm Message: (more…)
The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm. For discussing the problems related to the algorithm, we reviewed the reasons for the non-application of the algorithm and the reasons for dropout of patients (more…)
The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled tr ials that compared any of the three best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary (more…)